We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticle-Encapsulated Leelamine Shown Safe for Treating Malignant Melanoma

By LabMedica International staff writers
Posted on 02 Nov 2014
Print article
Image: Leelamine is a natural compound isolated from pine bark (Photo courtesy of Pennsylvania State College of Medicine).
Image: Leelamine is a natural compound isolated from pine bark (Photo courtesy of Pennsylvania State College of Medicine).
Image: In preclinical animal studies, the Nanolipolee-007 nano-liposome drug was shown to be both safe and effective against malignant melanoma (Photo courtesy of Melanovus Oncology).
Image: In preclinical animal studies, the Nanolipolee-007 nano-liposome drug was shown to be both safe and effective against malignant melanoma (Photo courtesy of Melanovus Oncology).
Cancer researchers have packaged an effective but highly toxic cancer drug into a nano-liposome package that can be delivered to malignant melanoma cells with minimal damage to surrounding normal tissues.

The drug, leelamine, which is a natural compound isolated from pine bark, is a diterpene compound and a weak agonist of the cannabinoid CB1 receptor. Leelamine has been reported to inhibit PDK (pyruvate dehydrogenase kinase) activity.

The PI3 kinase (PI3K), MAP kinase (MAPK), and STAT3 molecular pathways promote disease development by being constitutively activated in 50%–70% of melanomas. In earlier studies leelamine inhibited the growth of preexisting xenografted melanoma tumors by an average of 60% by targeting the PI3K, MAPK, and STAT3 pathways without affecting animal body weight or blood markers of major organ function. The mechanism of action of leelamine was mediated by disruption of cholesterol transport, causing decreased cellular proliferation and, consequently leading to increased tumor cell apoptosis as well as decreased tumor vascularization.

Unfortunately, leelamine is not a suitable drug for use in humans due to its poor bioavailability and lethality when administered intravenously. To overcome these limitations, investigators at The Pennsylvania State University College of Medicine (Hershey, USA) developed a delivery system for leelamine based on nanoparticle-sized liposomes. The nano-liposomes (nicknamed Nanolipolee-007) could be loaded stably with leelamine up to 60% of their volume.

Results published in the October 2014 edition of the journal Molecular Cancer Therapeutics revealed that the Nanolipolee-007 nanoparticles were as effective at killing melanoma cells as leelamine dissolved in DMSO and were more effective at killing cultured melanoma compared with normal cells. Mechanistically, the Nanolipolee-007 particles acted in a fashion identical to natural leelamine by inhibiting PI3K/Akt, STAT3, and MAPK signaling mediated through inhibition of cholesterol transport.

Nanolipolee-007 inhibited the growth of preexisting xenografted melanoma tumors by an average of 64% by decreasing cellular proliferation, reducing tumor vascularization, and increasing cellular apoptosis, with negligible toxicity.

“The drug is packaged into a lipid ball significantly smaller than the width of a hair to make it soluble in the blood stream and prevent negative side effects. The drug-containing nanoparticle ball then travels in the bloodstream to the tumor, where it accumulates and the drug is released in the tumor to kill the cancer cells,” said senior author Dr. Gavin Robertson, professor of pharmacology, pathology, dermatology, and surgery at The Pennsylvania State University College of Medicine. “This nanoparticle moves leelamine one step closer to the clinic. We now have a drug that has the potential to be given to humans that could not be done before.”

Pennsylvania State University has patented this discovery and has licensed it to Melanovus Oncology (Jensen Beach, FL, USA) to conduct a series of FDA-required studies to enable clinical testing of the drug in humans.

Related Links:

The Pennsylvania State University College of Medicine
Melanovus Oncology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Auto-Chemistry Analyzer
CS-1200

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.